Given the tremendous promise of RNA-based anti-cancer therapy, and the fact that both KRASG12Ci and PLK1i are currently under clinical development, we put forward the idea that concurrent targeting of KRAS with ST8SIA6-AS1 or PLK1 in KRASG12Ci-resistant patients is an open and prospective opportunity. Here, PLK1 is linked to cancer.